PRESS RELEASE

AgenT Announces Collaboration to Improve Early-Alzheimer's Detection Using Machine Learning

July 17, 2020 10:00 AM Central European Time

PARIS, France – AgenT, a life sciences company whose mission is to detect Alzheimer's early through a simple blood test, announced today its research collaboration with Stanford Alzheimer's Disease Research Center to enhance AgenT's artificial intelligence multiomics platform by training its neural network on Stanford ADRC plasma samples.

"Detecting Alzheimer's early is one of the biggest medical challenges of the 21st century. The complexity of Alzheimer's has made it challenging to find biomarkers for early stage detection when a potential treatment would be the more effective." stated Jérôme Braudeau, PhD, co-founder and CEO of AgenT. After a decade of research, AgenT team has identified specific biomarkers of Alzheimer's by applying advanced machine learning techniques to plasmatic multiomics analyses.

After a successful clinical proof of concept on 232 plasma samples in early 2020, AgenT aims to improve the generalizability of its patented blood biomarkers and the associated neural network on 500 additional plasma samples from international research institutes. To carry out this new development phase, AgenT is bringing together clinical and research centers expert in Alzheimer's disease, including Stanford ADRC. "Applying machine learning to this high quality multiomics database will enable the development of models which distinguish people with and without Alzheimer's with unprecedented accuracy" said Alkéos Michaïl, PhD, CTO of AgenT. Stanford ADRC will supply AgenT with plasma samples from Alzheimer's patients and controls collected at different stages of disease progression, which will enable AgenT to optimize its diagnostic algorithm. Professor Tony Wyss-Coray, PhD, is the Principal Investigator on the study for Stanford ADRC.

"Our vision is the identification of blood circulatory factors that are deregulated during aging or the progression of neurodegenerative disorders can serve as diagnostic biomarkers or enable an effective treatment of Alzheimer's patients." said Jérôme Braudeau, PhD, co-founder and CEO of AgenT. "The research collaboration with Stanford ADRC is a unique opportunity to enhance the scientific understanding of Alzheimer's biology and its blood consequences. This study could pave the way for the prevention of dementia."

About AgenT

AgenT is a life sciences company whose mission is to detect Alzheimer's early through a simple blood test. By combining multiomics assays with advanced machine learning techniques to recognize Alzheimer's associated patterns, AgenT is developing a non-invasive blood test to detect Alzheimer's up to 20 years before the onset of the irreversible symptoms. Agent is headquartered in Paris, France.

For more information about AgenT, please visit www.agent-biotech.com.